Novartis India Limited (BOM: 500672)
India
· Delayed Price · Currency is INR 1,061.40
+6.45 (0.61%)
At close: Nov 14, 2024
Novartis India Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 3,451 | 3,351 | 3,787 | 3,999 | 3,814 | 4,383 | Upgrade
|
| Revenue | 3,451 | 3,351 | 3,787 | 3,999 | 3,814 | 4,383 | Upgrade
|
| Revenue Growth (YoY) | 5.97% | -11.53% | -5.28% | 4.86% | -12.98% | -10.69% | Upgrade
|
| Cost of Revenue | 2,056 | 2,000 | 2,017 | 1,782 | 1,467 | 1,826 | Upgrade
|
| Gross Profit | 1,395 | 1,351 | 1,771 | 2,217 | 2,346 | 2,556 | Upgrade
|
| Selling, General & Admin | 242 | 250.1 | 419.2 | 1,097 | 1,187 | 1,282 | Upgrade
|
| Other Operating Expenses | 365.9 | 443.9 | 686.2 | 789.3 | 868.7 | 1,134 | Upgrade
|
| Operating Expenses | 625 | 721.8 | 1,170 | 1,979 | 2,177 | 2,548 | Upgrade
|
| Operating Income | 770.3 | 629.2 | 600.8 | 237.7 | 168.7 | 8.4 | Upgrade
|
| Interest Expense | -6.1 | -14.9 | -17.5 | -48.3 | -76.8 | -63.9 | Upgrade
|
| Interest & Investment Income | 498.8 | 551.9 | 543.6 | 209.6 | 241.7 | 356.6 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.7 | -2.7 | -10.6 | 1.4 | -1.4 | -19.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 30 | 6 | 8.6 | 4.8 | 22.2 | 4.8 | Upgrade
|
| EBT Excluding Unusual Items | 1,290 | 1,170 | 1,125 | 405.2 | 354.4 | 286.8 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -496.4 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.9 | 32.1 | 28.9 | -1.4 | 45.5 | -0.4 | Upgrade
|
| Other Unusual Items | 0.6 | 26.8 | - | 54.4 | - | - | Upgrade
|
| Pretax Income | 1,239 | 1,228 | 1,154 | -38.2 | 400.4 | 286.4 | Upgrade
|
| Income Tax Expense | 364.8 | 376.5 | 120.2 | -1 | 191.4 | 185.6 | Upgrade
|
| Earnings From Continuing Operations | 874 | 851.9 | 1,034 | -37.2 | 209 | 100.8 | Upgrade
|
| Net Income | 874 | 851.9 | 1,034 | -37.2 | 209 | 100.8 | Upgrade
|
| Net Income to Common | 874 | 851.9 | 1,034 | -37.2 | 209 | 100.8 | Upgrade
|
| Net Income Growth | 14.14% | -17.58% | - | - | 107.34% | -80.53% | Upgrade
|
| Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Shares Change (YoY) | 0.04% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 35.39 | 34.50 | 41.86 | -1.51 | 8.46 | 4.08 | Upgrade
|
| EPS (Diluted) | 35.39 | 34.50 | 41.86 | -1.51 | 8.46 | 4.08 | Upgrade
|
| EPS Growth | 14.10% | -17.58% | - | - | 107.34% | -80.53% | Upgrade
|
| Free Cash Flow | 1,240 | 1,134 | 444.9 | 381.7 | -693 | -241.4 | Upgrade
|
| Free Cash Flow Per Share | 50.23 | 45.93 | 18.02 | 15.46 | -28.07 | -9.78 | Upgrade
|
| Dividend Per Share | - | 25.000 | 10.000 | 10.000 | 10.000 | 10.000 | Upgrade
|
| Dividend Growth | - | 150.00% | 0% | 0% | 0% | 0% | Upgrade
|
| Gross Margin | 40.43% | 40.32% | 46.75% | 55.44% | 61.52% | 58.33% | Upgrade
|
| Operating Margin | 22.32% | 18.78% | 15.86% | 5.94% | 4.42% | 0.19% | Upgrade
|
| Profit Margin | 25.33% | 25.42% | 27.29% | -0.93% | 5.48% | 2.30% | Upgrade
|
| Free Cash Flow Margin | 35.94% | 33.84% | 11.75% | 9.55% | -18.17% | -5.51% | Upgrade
|
| EBITDA | 761.3 | 631 | 618.4 | 256.5 | 199.9 | 47.3 | Upgrade
|
| EBITDA Margin | 22.06% | 18.83% | 16.33% | 6.41% | 5.24% | 1.08% | Upgrade
|
| D&A For EBITDA | -9 | 1.8 | 17.6 | 18.8 | 31.2 | 38.9 | Upgrade
|
| EBIT | 770.3 | 629.2 | 600.8 | 237.7 | 168.7 | 8.4 | Upgrade
|
| EBIT Margin | 22.32% | 18.78% | 15.86% | 5.94% | 4.42% | 0.19% | Upgrade
|
| Effective Tax Rate | 29.45% | 30.65% | 10.42% | - | 47.80% | 64.80% | Upgrade
|
| Revenue as Reported | 3,982 | 3,968 | 4,369 | 4,331 | 4,144 | 4,744 | Upgrade
|
| Advertising Expenses | - | 19.4 | 61 | 74.6 | 98 | 137.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.